Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Datavault AI Mengumumkan Partisipasinya dalam Pameran CES 2026 dan Info Terbaru untuk Investor tentang Divisi Akustik

View original at globenewswire.com
Datavault AI Mengumumkan Partisipasinya dalam Pameran CES 2026 dan Info Terbaru untuk Investor tentang Divisi Akustik PHILADELPHIA, Dec. 31, 2025 (GLOBE NEWSWIRE) -- melalui IBN -- Datavault AI Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • WiSA E adoption is increasing in decoder applications and premium audio products globally, supporting wider market penetration

    80% confidence

  • 2025 marks development and licensing partnerships with Dolby Technologies, WiSA product line advancements, innovative ADIO technology integration into events and advertising, and continued IP portfolio expansion as core company strategy

    80% confidence

  • VerifyU remains a core area for ongoing development and commercialization focus

    80% confidence

  • Engineering quality and ownership of crucial intellectual property is how WiSA became the standard in acoustics, reflecting product performance excellence and a culture that extends across all of Datavault AI

    80% confidence

  • All efforts are aimed at strengthening position as the sole source of breakthrough solutions

    80% confidence

Data points we hold from this source

Datavault AI Inc. · patent count63 patents
Datavault AI Inc. · new patents published9 patents
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com